Follistatin-like protein 1 and its role in inflammation and inflammatory diseases

Follistatin-like protein 1 (FSTL1) is a secreted glycoprotein produced mainly by cells of mesenchymal origin. FSTL1 has been shown to play an important role during embryogenesis; FSTL1-deficient mice die at birth from multiple developmental abnormalities. In the last decade, FSTL1 has been identifie...

Full description

Saved in:
Bibliographic Details
Published in:Immunologic research 2014-08, Vol.59 (1-3), p.266-272
Main Authors: Chaly, Yury, Hostager, Bruce, Smith, Sonja, Hirsch, Raphael
Format: Article
Language:English
Subjects:
Allergology
Animals
Arthritis, Experimental - genetics
Arthritis, Experimental - immunology
Arthritis, Experimental - pathology
Arthritis, Experimental - therapy
Biomarkers
Biomedical and Life Sciences
Biomedicine
Cells
Chemokines - genetics
Chemokines - immunology
Cytokines
Follistatin-Related Proteins - genetics
Follistatin-Related Proteins - immunology
Glycoproteins
Humans
Immune system
Immunology
Immunology at the University of Iowa
Inflammation - genetics
Inflammation - immunology
Inflammation - pathology
Inflammatory diseases
Internal Medicine
Medicine/Public Health
Mice
Mice, Mutant Strains
Portraits as Topic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Follistatin-like protein 1 (FSTL1) is a secreted glycoprotein produced mainly by cells of mesenchymal origin. FSTL1 has been shown to play an important role during embryogenesis; FSTL1-deficient mice die at birth from multiple developmental abnormalities. In the last decade, FSTL1 has been identified as a novel inflammatory protein, enhancing synthesis of proinflammatory cytokines and chemokines by immune cells in vitro and in vivo. FSTL1 mediates proinflammatory events in animal models of inflammatory diseases, particularly in collagen-induced arthritis in mice. FSTL1 is elevated in various inflammatory conditions and decreased during the course of treatment. FSTL1 may therefore be a valuable biomarker for such diseases. Moreover, a variety of experiments suggest that targeting of FSTL1 may be useful in the treatment of diseases in which inflammation plays a central role.
ISSN:0257-277X
1559-0755
DOI:10.1007/s12026-014-8526-z